Veraxa Biotech is trading 8.1% lower at $1.10, with no verified company-specific announcement explaining the decline. - The October 13 BiTAC-ADC proof-of-concept update is prior-day news and does not establish a reason for today’s move. - The biotech sector is down 2.01%, while the S&P 500 and Nasdaq are also lower amid hotter-than-expected headline inflation and renewed rate concerns. These pressures may be contributing, but a direct cause is unconfirmed.